Related Experiment Videos
Prognostic value of proliferating cell nuclear antigen in Wilms' tumour in children
G Skotnicka-Klonowicz1, J Kobos, E Łoś
1Clinic of Surgery and Paediatric Oncology, II Clinic of Children's Diseases, Institute of Paediatrics, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.
Insights
Proliferating Cell Nuclear Antigen (PCNA) is a valuable prognostic indicator in pediatric Wilms' tumors. Higher PCNA expression correlates with advanced stages and increased mortality, aiding in risk stratification.
Area of Science:
- Pediatric Oncology
- Cancer Biomarkers
- Tumor Biology
Background:
- Wilms' tumor is a common pediatric kidney cancer.
- Accurate prognostic factors are crucial for treatment stratification.
- Proliferating Cell Nuclear Antigen (PCNA) is a marker of cell proliferation.
Purpose of the Study:
- To assess the prognostic significance of PCNA in childhood Wilms' tumors.
- To determine the correlation between PCNA expression and clinical parameters.
- To evaluate PCNA as a predictor of patient outcomes.
Main Methods:
- Immunohistochemistry was used to quantify PCNA expression in 64 Wilms' tumor samples.
- Tumor tissues were analyzed using a monoclonal antibody.
- Children were treated according to SIOP and PPGGL protocols.
Main Results:
- PCNA expression varied widely (0-93%), with a mean of 30.5%.
- Elevated PCNA levels (>30%) correlated significantly with advanced tumor stage (P<0.01) and specific histological types (P<0.025).
- Higher PCNA index was associated with increased mortality (P<0.001).
Conclusions:
- PCNA serves as a significant prognostic factor in pediatric Wilms' tumors.
- PCNA expression can aid in identifying high-risk patients.
- Further research may integrate PCNA into risk-stratified treatment strategies.
Aims:
To evaluate the prognostic value of index Proliferating Cell Nuclear Antigen (PCNA) in Wilms' tumour in children.
Methods:
The study comprised 64 children aged from 2 days to 13 years treated according to the SIOP (Society International of Oncology Paediatric) and accepted by the PPGGL (Polish Paediatric Group for the Treatment of Solid Tumours). The studies were conducted on tumour tissue removed during surgery, fixed in formalin and embedded in paraffin blocks. Sections (4 microns) were evaluated by immunohistochemistry, using the peroxidase method to determine the expression of PCNA in Wilms' tumour cells by primary monoclonal antibody NCL-PCNA from Novocastra.
Results:
The percentage of immunopositive cells in particular fragments of the tumour ranged from 0--93%, mean 30.5%, median 25.5%. Mean and median values enabled division of children into two groups: Group A, where the percentage of cells staining with anti-PCNA was <30% and Group B, where this percentage was >30%. The expression of PCNA was evaluated in various stages of advancement, various histological types and depending on the course of disease. The studies revealed the correlation between index PCNA and stage of advancement P<0.01, index PCNA and histological type of Wilms' tumour P<0.025. Moreover we observed that deaths were found more frequently in tumours with index PCNA >30%, P<0.001.
Conclusions:
PCNA is a useful prognostic factor in Wilms' tumour in children.
